Investing in Tomorrow's Health
NCL Technology Ventures invests transformational equity capital in entrepreneurs who have truly innovative technologies.
Our Investment Strategy
We invest in Seed and Series A rounds where we can deploy our expertise and capital to help our companies achieve an early inflection point in valuation. We consciously choose investments that create an impact on the lives of patients as well as financial return for our investors.
Our Value Add:
We provide a package of human and capital resources over the life of our investments including:
- – Strong scientific knowledge and frontline healthcare experience
- – Developmental and leadership building experience
- – A carefully built local and global network of healthcare specialists
- – An overriding ambition to succeed in bringing new innovation in healthcare to benefit global recipients
“We are pleased with the performance of Fund 1 and have therefore decided to back Fund 2 as a cornerstone investor.”
– Health Technology Fund II LP
NCLs Health Technology Fund II
NCL has recently launched it Health Technology Fund II. The fund has been designed to take positions in pioneering new technologies that can create significant patient impact and produce upper quartile investment returns.
The fund has launched in partnership with several leading UK institutions including Kings College, NHS and our delivery partner Catalent Inc (NYSE: CLT). Documentation can be provided to professional investors only upon request.
Whether a potential investor or an entrepreneur we invite you to discuss your goals and ambitions with us.
Our team spans three generations and is vastly experienced in venture investment, fund structuring, entrepreneurship and business management and is supported by an expert Scientific Advisory Board.
Curesponse Secures Additional USD 8 Million Funding for Its Breakthrough Precision Oncology Platform
REẖOVOT, Israel, November 15, 2021 (Newswire.com) – Curesponse (www.curesponse.com) has secured additional USD 8 million funding for its breakthrough precision oncology platform. Curesponse is a cancer precision … Continued
Sana Health Receives FDA “Breakthrough Device Designation” for Sana Device as At-Home aid for Fibromyalgia
LAFAYETTE, CO Sana Health ( http:///www.sana.io ) , a Colorado-based medical technology startup backed by global hard tech investor firm SOSV and Founders Fund, … Continued
19th January 2021, London: Ampersand Health, experts in digital therapeutics for long-term inflammatory conditions, announce the launch of My Arthritis DTx to support people living with … Continued
Research by emteq labs reveals how emotion measurement could redefine treatment for anxiety, depression and PTSD
The AI Journal has covered the latest research by portfolio Emteq, acknowledging their current success milestones and the implications of their research for emotion … Continued